ArticlePloS one2014
Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Immunization of pigs with Actinobacillus pleuropneumonia live attenuated (gene-deleted) vaccine HB04M intramuscularly or intranasally exhibits remarkably rapid protection against heterologous strain challenge.BMC veterinary research · 2025Article
- Outer Membrane Vesicles fromACS nano · 2025Article
- Engineered Outer Membrane Vesicles for Antigen Delivery: Exploratory Study on Adjuvant Activity and Systemic Reactogenicity.Vaccines · 2025Article
- Investigation on antigen-specific T-cell responses induced by outer membrane vesicles fromFrontiers in immunology · 2025Article
- Mucosal adjuvanticity and mucosal booster effect of colibactin-depleted probioticHuman vaccines & immunotherapeutics · 2024Article
- Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Applied microbiology and biotechnology · 2024Review
- On-Demand Vaccine Production via Dock-and-Display of Biotinylated Antigens on Bacterial Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Construction and characterization of a hypervesiculation strain of Escherichia coli Nissle 1917.PloS one · 2024Article
- Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors.Theranostics · 2024Review
- Article
- A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens.Nature communications · 2023Article
- Tumor Colonization and Therapy byCancers · 2022Article
- A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles.NPJ vaccines · 2022Article
- Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.International journal of molecular sciences · 2022Review
- Biological Nanoparticles in Vaccine Development.Frontiers in bioengineering and biotechnology · 2022Review
- Probiotics, Their Extracellular Vesicles and Infectious Diseases.Frontiers in microbiology · 2022Review
- Outer Membrane Vesicles (OMVs) Produced by Gram-Negative Bacteria: Structure, Functions, Biogenesis, and Vaccine Application.BioMed research international · 2021Review
- SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.Journal for immunotherapy of cancer · 2020Article
- Glycine significantly enhances bacterial membrane vesicle production: a powerful approach for isolation of LPS-reduced membrane vesicles of probiotic Escherichia coli.Microbial biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Recombinant subunit vaccine engineering increasingly focuses on the development of more effective delivery platforms. However, current recombinant vaccines fail to sufficiently stimulate protective adaptive immunity against a wide range of pathogens while remaining a cost effective solution to global health challenges. Taking an unorthodox approach to this fundamental immunological challenge, we isolated the TLR-targeting capability of the probiotic E. coli Nissle 1917 bacteria (EcN) by engineering bionanoparticlate antigen carriers derived from EcN outer membrane vesicles (OMVs). Exogenous model antigens expressed by these modified bacteria as protein fusions with the bacterial enterotoxin ClyA resulted in their display on the surface of the carrier OMVs. Vaccination with the engineered EcN OMVs in a BALB/c mouse model, and subsequent mechanism of action analysis, established the EcN OMV's ability to induce self-adjuvanted robust and protective humoral and T(H)1-biased cellular immunity to model antigens. This finding appears to be strain-dependent, as OMV antigen carriers similarly engineered from a standard K12 E. coli strain derivative failed to generate a comparably robust antigen-specific TH1 bias. The results demonstrate that unlike traditional subunit vaccines, these biomolecularly engineered "pathogen-like particles" derived from traditionally overlooked, naturally potent immunomodulators have the potential to effectively couple recombinant antigens with meaningful immunity in a broadly applicable fashion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.